Deal Ends Today·Save 35% annual plan
CNS stimulant (Schedule II)Reviewed for 2026 plan year

Does Wellcare Cover Vyvanse?

The verdict

Covered on most plans

Wellcare covers Vyvanse on its Medicare Part D and Medicaid plans — generic lisdexamfetamine is the preferred option on the plan drug list, brand Vyvanse is non-preferred as generic supply improves. Wellcare is Centene-operated with minimal commercial/ACA presence; its readers are primarily Medicare and Medicaid enrollees who cannot use manufacturer coupons. A Schedule II 70 mg/day quantity limit and documented ADHD diagnosis are required; verify on your Wellcare plan drug list or state PDL.

MedicareCovered
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Wellcare drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Wellcare (Centene) focuses on Medicare Part D and Medicaid — Medicare and Medicaid members cannot use manufacturer savings cards for Vyvanse.

    Centene / Wellcare plan documentation; CMS rules

  • The DEA set the 2026 lisdexamfetamine APQ at 51,290,743 grams (effective January 5, 2026) to address supply shortfalls.

    DEA Final Order, effective January 5, 2026

  • Generic lisdexamfetamine costs ~$200–$360/month cash (or ~$60–$70 with coupon) versus brand Vyvanse at ~$400–$558/month.

    GoodRx cash price data

Plan types

Medicare vs. commercial coverage

Whether Wellcare covers Vyvanse depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Covered

Under Wellcare Medicare Part D plans (Wellcare's primary book), generic lisdexamfetamine is covered and preferred on the plan drug list; brand Vyvanse may require prior authorization as generic supply stabilizes. A Schedule II 70 mg/day quantity limit applies. Medicare Part D beneficiaries cannot use manufacturer savings cards — the generic is the affordable, preferred path. Verify on the Wellcare Part D drug list for your specific plan.

Commercial / Employer

Group & marketplace plans

Conditional

Wellcare has minimal commercial/employer plan presence — this is not a relevant LOB for most Wellcare members. Where Wellcare ACA/Individual plans are offered in select states, generic lisdexamfetamine is covered with QL and PA requirements. Wellcare Medicaid MCO plans (Centene-operated across multiple states) cover generic lisdexamfetamine per state PDL with PA and 70 mg/day QL; brand Vyvanse is non-preferred; nominal Medicaid cost-share applies. Verify on your Wellcare plan drug list and state Medicaid PDL — coverage criteria are state-variable.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Vyvanse require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Vyvanse actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Generic lisdexamfetamine: ~$200–$360 per month cash (as low as ~$60–$70 with coupon). Brand Vyvanse: ~$400–$558 per month. Estimates only — varies by pharmacy and dose.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Medicare Part D: tier-dependent and phase-dependent cost-share; verify on Wellcare Part D drug list. Medicaid: nominal ($0–$4 typical). Note: Medicare and Medicaid beneficiaries cannot use manufacturer coupons — the generic is the only cost-effective path.

Typical monthly copay once prior authorization is approved.

All dollar figures are estimates. Medicare and Medicaid members cannot use manufacturer savings cards. Verify your cost-share on the Wellcare plan drug list or by calling Wellcare member services.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Search the Wellcare plan drug list

    Log in to your Wellcare member account at wellcare.com and use the drug list search to look up 'lisdexamfetamine' or 'Vyvanse.' The tool shows the tier, quantity limit, and any PA requirement for your specific Wellcare Part D or Medicaid plan. Plan drug lists are updated annually and sometimes mid-year.

  2. 2

    Call Wellcare Member Services

    Call the number on the back of your Wellcare card to confirm Vyvanse coverage on your specific plan — whether generic or brand applies, your cost-share, and how to initiate prior authorization. For Medicaid enrollees, also check with your state Medicaid office for state-PDL requirements.

  3. 3

    Have your prescriber submit PA and check pharmacy stock

    If prior authorization is required, your prescriber provides your ADHD or BED diagnosis documentation. Ask your pharmacy about current generic lisdexamfetamine availability — if it is out of stock, your prescriber can document the shortage for Wellcare to approve brand Vyvanse. Generic supply varies by region and pharmacy.

If it's denied

Options if Wellcare won't cover Vyvanse

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Generic lisdexamfetamine

The Wellcare plan drug list-preferred option. FDA-approved August 2023; ~$60–$70/month with coupon vs. $400–$558 for brand Vyvanse. Therapeutically equivalent to brand — the only affordable option for Medicare and Medicaid members without manufacturer coupons.

Generic amphetamine/dextroamphetamine (Adderall generic)

FDA-approved for ADHD with a ~60 mg/day QL. Generally preferred on Part D and Medicaid formularies when amphetamine salts are available.

Generic methylphenidate (Ritalin)

Non-amphetamine Schedule II stimulant for ADHD. Generally covered on Medicaid and Part D formularies at a low tier.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

Yes. Wellcare Medicare Part D plans cover Vyvanse — generic lisdexamfetamine is preferred on the plan drug list, brand Vyvanse may require prior authorization as generic supply stabilizes. A 70 mg/day quantity limit applies. Important for Medicare members: you cannot use Takeda's Vyvanse savings card on a Medicare plan — manufacturer coupons are prohibited for Medicare beneficiaries by federal law. The generic is the affordable, covered path. Verify your specific Part D plan drug list at wellcare.com.

Wellcare Medicaid MCO plans (Centene-operated in multiple states) cover generic lisdexamfetamine per state preferred drug list with prior authorization and a 70 mg/day quantity limit; brand Vyvanse is non-preferred. Coverage criteria vary by state — some states apply different age-based PA requirements and formulary tiers. Medicaid members pay nominal cost-share ($0–$4 typically). Verify on your Wellcare Medicaid plan drug list and your state Medicaid PDL, as state-specific rules apply.

Both Wellcare and Humana are Medicare Part D-centric carriers covering generic lisdexamfetamine as preferred, with brand Vyvanse requiring PA. The key differences: Humana's page centers on the older-adult cardiovascular-safety review that Part D prescribers document for stimulant PA in that population. Wellcare's page centers on Centene's plan-drug-list and state-PDL criteria across Medicaid, and the coupon exclusion for both Medicare and Medicaid enrollees. Both carriers follow similar generic-preferred logic; verify on your specific plan drug list.

Yes. If generic lisdexamfetamine is unavailable at your pharmacy due to the ongoing stimulant shortage, a pharmacist override or shortage-documented prior authorization can allow brand Vyvanse dispensing on Wellcare. Contact your pharmacy first to confirm the generic is truly out of stock, then have your prescriber document the shortage in a PA request to Wellcare. Supply has been improving since the DEA raised the 2026 lisdexamfetamine production quota to 51.3 million grams, but regional and pharmacy-level availability still varies.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.